Surgical Management of the Axilla in Patients Presenting with Clinically Node Positive Hormone Receptor Positive, HER2 Negative (HR+/HER2-) Breast Cancer

被引：0
|
作者：
Jasper, Jacob [1 ]
Kantor, Olga [2 ]
Dorninici, Laura [3 ]
Nakhlis, Faina [4 ]
Ogayo, Esther [5 ]
Nimbkar, Suniti [6 ]
Kurt, Busem Binbogct [5 ]
King, Tari [7 ]
Mittendorf, Elizabeth [7 ]
机构：
[1] Tufts Univ, Medford, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Brigham & Womens Faulkner Hosp, Dana Farber Canc Inst, Boston, MA USA
[4] Brigham & Womens Hosp, Boston, MA USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Dana Farber Brigham Canc Ctr, South Shore Hosp clin, Boston, MA USA
[7] Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2024年 / 31卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E44
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [31] Comparison of EndoPredict and MammaPrint in hormone receptor positive, HER2 negative breast cancer
    Boesl, A.
    Spitzmueller, A.
    Haid, A.
    Jasarevic, Z.
    Baruschke, K.
    Jaeger, S.
    Offner, F.
    BREAST, 2015, 24 : S46 - S47
  • [32] Survival of metastatic hormone receptor (HR) positive/HER2 negative; HER2+; and triple negative (TN) breast cancer based on initial presentation
    den Brok, Wendie-Lou D.
    Speers, Caroline
    Lovedeep, Gondara
    Baxter, Emily
    Tyldesley, Scott
    Caroline, Lohrisch
    CANCER RESEARCH, 2015, 75
  • [33] Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
    Bianchini, Giampaolo
    Malorni, Luca
    Arpino, Grazia
    Zambelli, Alberto
    Puglisi, Fabio
    Del Mastro, Lucia
    Colleoni, Marco
    Montemurro, Filippo
    Bianchi, Giulia
    Paris, Ida
    Allegrini, Giacomo
    Cazzaniga, Marina Elena
    Orditura, Michele
    Zamagni, Claudio
    Tamberi, Stefano
    Castelletti, Daniela
    Benelli, Matteo
    Callari, Maurizio
    Santoro, Angela
    De Laurentiis, Michelino
    CANCER RESEARCH, 2022, 82 (04)
  • [34] Patterns of treatment and outcome of palbociclib plus endocrine therapy in hormone receptor-positive (HR+)/HER2 receptor-negative (HER2-) metastatic breast cancer (MBC): A real life multicenter Italian study
    Palumbo, R.
    Torrisi, R.
    Quaquarini, E.
    Sottotetti, F.
    Gambaro, A.
    Collova, E.
    Ferzi, A.
    Fava, S.
    Agostinetto, E.
    Tagliaferri, B.
    Licata, L.
    Teragni, C.
    Bernardo, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [35] Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).
    Moy, B.
    Lebrun, F.
    Bellet, M.
    Chow, L.
    Lang, I.
    Xu, B.
    Badwe, R. A.
    Hershman, D. L.
    Leip, E.
    Bardy-Bouxin, N.
    Duvillie, L.
    Neven, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2
    Sonke, G. S.
    Hart, L. L.
    Campone, M.
    Erdkamp, F.
    Janni, W.
    Verma, S.
    Villanueva, C.
    Jakobsen, E.
    Alba, E.
    Wist, E.
    Favret, A. M.
    Bachelot, T.
    Hegg, R.
    Wheatley-Price, P.
    Souami, F.
    Sutradhar, S.
    Miller, M.
    Germa, C.
    Burris, H. A.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S1 - S2
  • [37] Characterization of the tumor microenvironment in patients with hormone receptor positive, HER2 negative early breast cancer
    Kearney, Matthew Ryan
    Vanguri, Rami
    Wang, Qi
    Fenn, Kathleen
    Guo, Hua
    Marks, Douglas
    Hibshoosh, Hanina
    Kalinsky, Kevin M.
    Connolly, Eileen
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Unmet clinical need in patients with pre-treated hormone receptor- positive/HER2-negative (HR+/HER2-) metastatic breast cancer in routine care: a targeted literature review
    Spring, Laura
    Collin, Simon M.
    Dhillon, Inderjit K.
    Long, Grainne
    Bertranou, Evelina
    Jhaveri, Komal
    Bardia, Aditya
    CANCER RESEARCH, 2024, 84 (09)
  • [39] APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD)
    Chumsri, Saranya
    Raskina, Kira
    Sammons, Sarah
    Alder, Laura
    Danziger, Natalie
    Schrock, Alexa B.
    McGregor, Kim
    Sokol, Ethan
    CANCER RESEARCH, 2022, 82 (04)
  • [40] Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
    Malorni, L.
    De laurentiis, M.
    Bianchini, G.
    Zambelli, A.
    Puglisi, F.
    Bianchi, G. V.
    Del Mastro, L.
    Paris, I.
    Montemurro, F.
    Allegrini, G.
    Colleoni, M. A.
    Tamberi, S.
    Zamagni, C.
    Cazzaniga, M. E.
    Orditura, M.
    Guarneri, V.
    Castelletti, D.
    Benelli, M.
    Di Marino, M.
    Arpino, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S492 - S492
12345